Akari Therapeutics forms advisory board, appoints oncologist Hurvitz

Akari Therapeutics Plc (NASDAQ: AKTX) announced the formation of its Scientific Advisory Board and appointed Dr. Sara A. Hurvitz as its inaugural member, according to a company press release.

Dr. Hurvitz serves as Professor of Medicine and Division Head of Hematology/Oncology at the University of Washington School of Medicine and as Senior Vice President of the Clinical Research Division at Fred Hutchinson Cancer Center. She previously directed the breast oncology program at UCLA, where she joined the faculty in 2006.

The oncologist has led clinical trials across all phases of development and focuses on antibody drug conjugates (ADCs) and targeted therapies for breast cancer. She received the European Society of Medical Oncology Breast Cancer Award in 2023 and the Marni Levine Memorial Breast Cancer Research Award from 2008 through 2015.

"The formation of our SAB marks an important step in advancing Akari's scientific and clinical strategy," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics.

Dr. Hurvitz earned her MD from the University of Southern California and completed a hematology-oncology fellowship at UCLA in 2006. She holds board certifications in internal medicine, hematology, and medical oncology.

Akari Therapeutics develops ADCs for oncology applications. The company's lead candidate, AKTX-101, targets the Trop2 receptor and uses a proprietary PH1 payload designed to disrupt RNA splicing within cancer cells. The company also has AKTX-102 in development with an undisclosed target.

You May Also Be Interested In

• Worthington Enterprises raises dividend 5%, adds board member
• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Ambiq prices upsized public offering at $78 per share